Actinogen launches discounted share purchase plan to fund Alzheimer’s trial

An announcement from Actinogen Medical ( (AU:ACW) ) is now available.

Actinogen Medical has launched a share purchase plan offering eligible shareholders in Australia and New Zealand, and a limited number of U.S. employees, the chance to buy up to $30,000 of new shares at $0.042 each without brokerage. The offer price matches a recent institutional placement and represents a discount to the last traded price and recent VWAP, with the company targeting up to $5 million in proceeds and reserving the right to scale back applications.

The share purchase plan follows firm commitments of about $12 million under a separate placement, of which roughly $11.3 million has already been raised, with the balance subject to shareholder approval. Funds from both the placement and the plan will be directed to completing the XanaMIA pivotal Alzheimer’s trial, implementing its open-label extension, providing working capital, and covering capital raising costs, potentially accelerating Actinogen’s clinical and operational progress in Alzheimer’s drug development.

The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical Limited is an Australia-based biotechnology company focused on developing therapies for neurological disorders, particularly Alzheimer’s disease. The company’s lead program is the XanaMIA pivotal trial in Alzheimer’s, supported by associated open-label extension studies, positioning it within the neurodegenerative drug development market.

YTD Price Performance: -29.51%

Average Trading Volume: 6,164,363

Technical Sentiment Signal: Hold

Current Market Cap: A$137.3M

Learn more about ACW stock on TipRanks’ Stock Analysis page.